| Objective The clinical characteristics of patients with breast cancer therapy-related hematological neoplasms were studied.The possible causes,mechanisms and prognosis of breast cancer therapy related hematological neoplasms were investigated and analyzed.Methods Retrospective analysis was conducted to investigate the clinical data of 17 inpatients with breast cancer therapy-related hematological neoplasms from May 2006 to December 2017 in General Hospital of Ningxia Medical University.The data of the cases were analyzed comprehensively and the related literatures were reviewed.Results Among 11 years,our hospital received a total of 17 case of breast cancer therapy-related hematological neoplasms patients,there were 14 cases of therapy-related acute myeloid leukemia and 3 cases of therapy-related non-hodgkin’s lymphoma.The median latency of breast cancer to therapy-related hematological neoplasms was 58(10-246)months,the median survival period was 11.50(1-37)months.Six patients(35.3%)had a family history of cancer in first-or second-degree relatives.Among the 10 patients with acute myeloid leukemia,chromosome karyotyping demonstrated 70.0%(7/10)patients had complex karyotype,molecular genetic examination revealed 2 patients with BCR-ABL fusion gene,1 case with MLL-ELL fusion gene,1 case with MLL-AF9 fusion group,1 case with AML1-ETO fusion gene,1 case with HOX11 point mutation,1 case with FLT3-ITD gene mutation and AML1-ETO fusion gene.Conclusions Breast cancer patients after radiotherapy and chemotherapy adjuvant treatment were often with karyotype abnormality and molecular genetic abnormality and had a poor prognosis.For younger than 65 years old breast cancer patients with a family history of cancer,the choice of chemotherapy and radiation regimen should be cautious and be individualized.Karotyping and molecular genetic examination may be used to supervise and assess the prognosis of therapy-related hematological neoplasms. |
PDF Full Text Request